AVD 302
Alternative Names: AVD-302Latest Information Update: 28 Sep 2020
At a glance
- Originator Aviceda Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Diabetic retinopathy
Most Recent Events
- 21 Sep 2020 AVD 302 is available for licensing as of 21 Sep 2020. https://www.avicedarx.com/
- 21 Sep 2020 Early research in Diabetic retinopathy in USA (Parenteral), prior to September 2020 (Aviceda Therapeutics pipeline, September 2020)